Prescription drug · ANDA
Acitretin NDC 46708-743
Acitretin 25 mg/1 · Capsule · Oral · Alembic Pharmaceuticals Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 46708-743-30 | 46708074330 | 30 CAPSULE in 1 BOTTLE (46708-743-30)Marketed from Aug 8, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Acitretin
- Generic name (nonproprietary)
- acitretin
- Active ingredients
- Acitretin — 25 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Alembic Pharmaceuticals LimitedNDC labeler code 46708
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 217774
- Marketing start
- Listing expires
- Other FDA classes
- Retinoids (Chemical structure)
- Identifiers
- Product ID 46708-743_77011f2b-a2e7-4a43-9ff3-29d73f322319SPL ID 77011f2b-a2e7-4a43-9ff3-29d73f322319SPL set ID 77011f2b-a2e7-4a43-9ff3-29d73f322319RxCUI 199689, 199690, 894859UNII LCH760E9T7
- Pharmacologic class
- Retinoid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N446708074330followed by a unit qualifier and the quantityPackage 46708-0743-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, acitretin capsules should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential, acitretin capsules should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed CONTRAINDICATIONS AND WARNINGS — acitretin capsules can cause severe birth defects). Most patients experience relapse of psoriasis after discontinuing therapy. Subsequent courses, when clinically indicated…
Excerpt only. Read the full label for complete information.
About NDC 46708-743
- What is NDC 46708-743?
- 46708-743 is the product NDC for Acitretin, Acitretin 25 mg/1 capsule, listed with the FDA by Alembic Pharmaceuticals Limited. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Acitretin.
- What is the active ingredient?
- Acitretin.
- Who is the labeler?
- Alembic Pharmaceuticals Limited, NDC labeler code 46708. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Acitretin?
- 21 other product NDCs are listed under this name. See all Acitretin NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Acitretin products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Acitretin | Acitretin 10 mg/1 | CapsuleOral | Alembic Pharmaceuticals Limited | 46708-741 | 46708-0741-30 |
| Acitretin | Acitretin 17.5 mg/1 | CapsuleOral | Alembic Pharmaceuticals Limited | 46708-742 | 46708-0742-30 |
| Acitretin | Acitretin 10 mg/1 | CapsuleOral | Alembic Pharmaceuticals Inc. | 62332-741 | 62332-0741-30 |
| Acitretin | Acitretin 17.5 mg/1 | CapsuleOral | Alembic Pharmaceuticals Inc. | 62332-742 | 62332-0742-30 |
| Acitretin | Acitretin 25 mg/1 | CapsuleOral | Alembic Pharmaceuticals Inc. | 62332-743 | 62332-0743-30 |
| Acitretin | Acitretin 10 mg/1 | CapsuleOral | AvKARE | 42291-086 | 42291-0086-30 |
| Acitretin | Acitretin 17.5 mg/1 | CapsuleOral | AvKARE | 42291-087 | 42291-0087-30 |
| Acitretin | Acitretin 25 mg/1 | CapsuleOral | AvKARE | 42291-088 | 42291-0088-30 |
| Acitretin | Acitretin 10 mg/1 | CapsuleOral | Mylan Pharmaceuticals Inc. | 0378-7020 | 00378-7020-93 |
| Acitretin | Acitretin 25 mg/1 | CapsuleOral | Mylan Pharmaceuticals Inc. | 0378-7023 | 00378-7023-93 |
Other NDCs under ANDA 217774
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Acitretin | Acitretin 10 mg/1 | CapsuleOral | Alembic Pharmaceuticals Limited | 46708-741 |
| Acitretin | Acitretin 17.5 mg/1 | CapsuleOral | Alembic Pharmaceuticals Limited | 46708-742 |
| Acitretin | Acitretin 10 mg/1 | CapsuleOral | Alembic Pharmaceuticals Inc. | 62332-741 |
| Acitretin | Acitretin 17.5 mg/1 | CapsuleOral | Alembic Pharmaceuticals Inc. | 62332-742 |
| Acitretin | Acitretin 25 mg/1 | CapsuleOral | Alembic Pharmaceuticals Inc. | 62332-743 |